Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4 (TLR4) agonist with more than 100,000 human doses safely administered as a part of licensed hepatitis B and Human papillomavirus vaccines [6]. This evidence concerns the gene TLR4 and hepatitis B virus infection.